Showing 1851-1860 of 3314 results for "".
- NIH-Led Science Team Defines Elements of Cerebral Vision Impairmenthttps://modernod.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/Cerebral (or cortical) vision impairment (CVI) is a leading cause of childhood vision impairment in the United States and other industrialized nations, affecting at least 3% of primary school children. As vision is closely tied to learn
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Alcon Unveils PRECISION7 1-Week Contact Lens with ACTIV-FLO Technologyhttps://modernod.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/Alcon announced the US launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO system, these lenses are designed to deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. [1]
- Johnson & Johnson Presents New Data on ACUVUE OASYS MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-presents-new-data-on-acuvue-oasys-max-1-day-contact-lenses/2482523/Johnson & Johnson will present data at Academy of Optometry 2024 on the ACUVUE OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologie
- GenSight Biologics Publishes Meta-Analysis on Efficacy of Treatments for Leber Hereditary Optic Neuropathyhttps://modernod.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/GenSight Biologics announced the publication of a meta-analysis evaluating visual outcomes in patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation. This mutation, known as ND4-LHON, is the most common cause of the disease and is associated with the
- New Report by Contact Lens Institute Reveals Strategies to Enhance Contact Lens Retentionhttps://modernod.com/news/new-report-by-contact-lens-institute-reveals-strategies-to-enhance-contact-lens-retention/2482520/The Contact Lens Institute (CLI) has just published an in-depth, data-driven report titled “Disrupting the Dropout Dilemma: Practical Steps to Keep Patients in Contact Lenses.” Aimed at assisting eye care
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- Zeiss Launches Micor 700 Lens Extraction Devicehttps://modernod.com/news/zeiss-launches-micor-700-lens-extraction-device/2482459/Zeiss announced the US launch of the Micor 700 lens extraction device, which is designed to eliminate the need for ultrasound, offering a more sustainable and cost-effective solution while expanding the intraocular working space for surgeons. The Micor 700 will debut
- Opthea Announces Executive Leadership Changes and Senior Hireshttps://modernod.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/Opthea announced several executive leadership changes aimed at bolstering the company’s commercial and clinical expertise as it prepares for the anticipated 2025 topline data readout of phase 3 trials for its lead candidate, sozinibercept, in wet AMD. Daniel Geffken, Co-Founder an